Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus SSD AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus SSD AF.
BENZAMYCIN vs SSD AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Apply a thin layer topically once or twice daily to affected area.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic